Canagliflozin (hemihydrate): Precision SGLT2 Inhibitor for Glucose Metabolism Research

Executive Summary: Canagliflozin (hemihydrate) is a rigorously characterized small molecule SGLT2 inhibitor for research applications, with ≥98% purity confirmed by HPLC and NMR (product page). It specifically blocks the renal sodium-glucose co-transporter 2, promoting urinary glucose excretion and lowering blood glucose levels (see advanced mechanistic insights). The compound is insoluble in water but dissolves readily in DMSO (≥83.4 mg/mL) and ethanol (≥40.2 mg/mL) at ambient conditions. Recent peer-reviewed screens confirm that Canagliflozin (hemihydrate) does not inhibit the mTOR pathway, ensuring specificity for SGLT2-centric research (Breen et al., 2025). This article synthesizes validated data and clarifies common misconceptions about its applications and boundaries.

Biological Rationale

Sodium-glucose co-transporter 2 (SGLT2) is a membrane protein expressed primarily in the proximal tubules of the renal cortex. It facilitates the reabsorption of filtered glucose from the glomerular filtrate. Inhibition of SGLT2 leads to increased urinary glucose excretion, directly lowering systemic blood glucose concentrations. Canagliflozin (hemihydrate), also known as JNJ 28431754 hemihydrate, offers a selective approach to modulate glucose homeostasis pathways in both normal and diabetic models (detailed mechanistic review). Unlike mTOR inhibitors—which target nutrient sensing and protein synthesis at the cellular level—SGLT2 inhibitors act upstream in the kidney, providing metabolic control without direct interference in cell growth or proliferation pathways. This selectivity is especially valuable in metabolic disorder research, enabling targeted intervention without confounding effects from unrelated signaling cascades.

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin (hemihydrate) binds competitively to the SGLT2 protein, blocking glucose reabsorption in the proximal renal tubule. This blockade leads to increased glucose excretion in urine (glucosuria) and a concomitant reduction in plasma glucose levels. The molecular formula is C₂₄H₂₆FO_5.5S, with a molecular weight of 453.52 g/mol. The compound is supplied as a hemihydrate form, enhancing storage stability at -20°C. For in vitro assays, Canagliflozin (hemihydrate) is dissolved in organic solvents such as DMSO or ethanol; aqueous solubility is negligible. It does not inhibit mTOR or TOR pathways, as rigorously validated in recent yeast-based pathway screens (Breen et al., 2025). Instead, its pharmacological action is restricted to glucose transport, making it a precise probe for dissecting glucose homeostasis mechanisms. The selectivity profile has been cross-validated in both mammalian and non-mammalian models, confirming the absence of off-target effects on protein kinase signaling (comparative pathway analysis).

Evidence & Benchmarks

• Canagliflozin (hemihydrate) exhibits ≥98% purity, confirmed by HPLC and NMR under standard analytical conditions (ApexBio product documentation).
• The compound is insoluble in water but soluble in DMSO at concentrations ≥83.4 mg/mL and in ethanol at ≥40.2 mg/mL (25°C, pH-neutral) (ApexBio).
• Storage at -20°C is recommended to preserve stability; shipping is performed with blue ice for small molecules (ApexBio).
• Canagliflozin (hemihydrate) does not inhibit mTOR or TOR pathways in yeast-based drug sensitivity models, unlike rapamycin, Torin1, or omipalisib (GSK2126458) (Breen et al., 2025, DOI).
• It selectively inhibits SGLT2, promoting renal glucose excretion and lowering blood glucose, validated in cellular and animal models (mechanistic insights).

Applications, Limits & Misconceptions

Canagliflozin (hemihydrate) is employed as a high-specificity tool in glucose metabolism, diabetes mellitus, and metabolic disorder research. It is optimized for in vitro and in vivo studies on renal glucose handling, transporter selectivity, and metabolic pathway dissection. Some recent literature suggests potential off-target effects for SGLT2 inhibitors, but rigorous experimental screens confirm that Canagliflozin (hemihydrate) does not inhibit mTOR or related protein kinases under standard research conditions (Breen et al., 2025). Researchers should not infer mTOR or TORC1/2 pathway involvement when using this compound (strategic integration article). This article provides a more granular experimental contrast to prior overviews by focusing on validated pathway boundaries.

Common Pitfalls or Misconceptions

• Does not inhibit mTOR: No evidence for TOR/mTOR pathway inhibition in yeast or mammalian models under standard assay conditions (Breen et al., 2025).
• Not a general kinase inhibitor: Canagliflozin (hemihydrate) does not broadly inhibit protein kinases; activity is confined to SGLT2.
• Water insolubility: The compound must be dissolved in DMSO or ethanol, not aqueous buffers, for experimental use.
• For research use only: Not for diagnostic, therapeutic, or clinical applications.
• Solution stability: Prepared solutions should not be stored long-term; use promptly to maintain efficacy.

Workflow Integration & Parameters

For successful integration into experimental workflows, Canagliflozin (hemihydrate) should be stored at -20°C and protected from moisture and light. Stock solutions are best prepared in DMSO or ethanol immediately prior to use. Working concentrations depend on the model system: 1–10 μM for in vitro cell-based assays; animal dosing regimens should be guided by peer-reviewed protocols. Quality control is assured by batch-specific HPLC and NMR certificates. Researchers investigating glucose homeostasis, renal reabsorption, or metabolic disease mechanisms benefit from the compound's selectivity and validated lack of off-target kinase effects. For more nuanced pathway integration and systems biology perspectives, see this systems biology review, which Canagliflozin (hemihydrate) extends by focusing exclusively on transporter specificity.

Conclusion & Outlook

Canagliflozin (hemihydrate) is a rigorously validated, high-purity SGLT2 inhibitor for advanced metabolic research. Its specificity for renal glucose reabsorption and lack of mTOR pathway inhibition have been conclusively demonstrated (Breen et al., 2025). This makes it an indispensable tool for elucidating glucose homeostasis pathways, benchmarking new metabolic models, and developing translational strategies in diabetes research. For complete specifications and ordering, refer to the C6434 kit product page.